Application of inosinic acid in preparation of product with inhibition effect on bacteria

By using inosine to inhibit the growth of bacteria carried by polymyxin, carbapenems and tigecycline resistance genes, the problem of insufficient therapeutic effect of existing antibiotics on drug-resistant bacteria has been solved, and a variety of cases have been achieved. Effective inhibition and safe therapeutic effects of drug-resistant bacteria.

CN118924780AActive Publication Date: 2024-11-12CHINA AGRI UNIV

Patent Information

Application Number
CN202411253304.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-11-12
Estimated Expiration
2044-09-09

AI Technical Summary

Technical Problem

Existing antibiotics are poor in the treatment of bacterial infections that are resistant to polymyxins, carbapenems and tigecyclines, and the spread of drug-resistant genes leads to a threat to public health safety.

Method used

Products that use inosine as the main active ingredient to inhibit the growth of bacteria carried by polymyxin, carbapenems and tigecycline resistance genes, including E. coli, Acinetobacter baumannii, and Pseudomonas aeruginosa Inhibition of bacteria, etc.

Benefits of technology

Inosine significantly inhibits the growth of a variety of drug-resistant bacteria and is not easy to induce drug resistance, providing a potential treatment option to combat drug-resistant bacterial infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924780A_ABST
    Figure CN118924780A_ABST
Patent Text Reader

Abstract

The invention discloses an application of inosinic acid in preparation of a product with an inhibition effect on bacteria, and the bacteria in the invention can be bacteria with drug resistance to antibiotics and / or containing drug-resistant genes, and also can be other bacteria sensitive to the antibiotics. The invention discloses application of inosinic acid in preparation of a product with an inhibition effect on bacteria, and experiments prove that the inosinic acid has a good sterilization effect on various drug-resistant bacteria, does not easily induce formation of drug resistance, and can be used as a potential active component for resisting infection of the drug-resistant bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology and relates to the application of inosinic acid in preparing a product having an inhibitory effect on bacteria. Background Art

[0002] Bacterial infections pose a threat to human and animal health. The emergence of drug-resistant, multidrug-resistant and even pan-drug-resistant bacteria makes the treatment of clinical bacterial infectious diseases more difficult. Polymyxins and β-lactam antibiotics play a key role in resisting bacterial infections. Carbapenems in β-lactam antibiotics are particularly effective against Gram-negative bacteria. However, plasmid-borne polymyxin resistance genes ( mcr ) and carbapenem resistance genes ( bla ) mediated the bacterial resistance to these two types of antibiotics, resulting in a sharp decline in the antibacterial ability of the drugs. Nowadays, multiple drug-resistant genes have spread globally, posing a challenge to public health security.

[0003] In order to cope with the current severe situation of drug resistance, it is urgent to find new drugs to fight against drug-resistant bacteria. Summary of the invention

[0004] The purpose of the present invention is to provide a novel compound for resisting drug-resistant bacteria, especially bacteria resistant to antibiotics such as polymyxin, carbapenems, tigecycline, etc.

[0005] In a first aspect, the present invention provides the use of inosinic acid in the preparation of a product having an inhibitory effect on drug-resistant bacteria, wherein the drug-resistant bacteria are resistant to antibiotics, and the antibiotics are selected from at least one of A1) to A3): A1) Polymyxins; A2) Carbapenems; A3) Tigecycline.

[0006] In the present invention, inosinemonphosphate (IMP) is referred to as IMP in English, and its structure is shown in Formula 1: Formula 1.

[0007] In the above applications, inosinic acid can inhibit the growth of antibiotic-resistant bacteria.

[0008] In the above application, the drug-resistant bacteria resistant to antibiotics may contain a drug-resistant gene. Specifically, the drug-resistant gene is selected from at least one of B1) to B3): B1) Polymyxin resistance genes; B2) Carbapenem resistance genes; B3) Tigecycline resistance gene.

[0009] Furthermore, the polymyxin resistance gene refers to a gene that can make bacteria resistant to polymyxin. The polymyxin resistance gene can be a polymyxin resistance gene mcr (mobile colistin resistance) 。The mcr Can mcr-1 , mcr-2 , mcr-3 , mcr-4 , mcr-5 , mcr-6 , mcr-7 , mcr-8 , mcr-9 , mcr-10 at least one subtype. mcr The gene is mainly transmitted horizontally between bacteria through plasmids, making the bacteria resistant to the effects of polymyxins. mcr-1 Gene, mcr-1 The coding region is 1626bp long, and its nucleotide sequence is positions 327-1952 of SEQ ID NO: 1. It can encode an enzyme with phosphoethanolamine transfer function, which reduces the negative charge on the bacterial surface by transferring the phosphoethanolamine group to the lipid A part of lipopolysaccharide, thereby reducing the affinity of polymyxin to the bacterial outer membrane, leading to the generation of polymyxin resistance.

[0010] The carbapenems include imipenem, meropenem and ertapenem, etc., and the carbapenem resistance gene refers to a gene that can make bacteria resistant to carbapenem drugs. bla The gene encodes the enzyme NDM-1, which can hydrolyze a variety of β-lactam antibiotics including carbapenems, making the bacteria resistant to these antibiotics. bla Genes include bla KPC , bla NDM , bla IMP , bla VIM Etc. Further, bla NDM Genes include bla NDM-1 , bla NDM-5 , bla NDM-4 , bla NDM-7 , bla NDM-9 Etc. Among them, blaNDM-1 The coding region is 813 bp in length, and its nucleotide sequence is positions 319-1131 of SEQ ID NO:2.

[0011] The tigecycline resistance gene refers to tet (X) The tet(X) gene family causes high-level bacterial resistance to tigecycline. The tet(X) gene encodes a flavin adenine dinucleotide (FAD)-dependent monooxygenase that can inactivate all tetracyclines, including tigecycline, through chemical modification. tet(X) Genes mainly include tet (X2), tet(X3) , tet(X4) and tet(X5) .

[0012] In the above application, the product can be a medicine, in which inosinic acid is the main active ingredient. It is understandable that the active ingredients of the medicine may include other substances in addition to inosinic acid.

[0013] Furthermore, the dosage form of the drug is selected from any one of tablets, capsules, granules, oral liquids, suspensions, sprays, inhalants, ointments, lotions, gels, eye drops, suppositories, transdermal patches, injections or lyophilized powder injections.

[0014] In the above application, the drug-resistant bacteria is selected from at least one of C1)-C6): C1) Escherichia coli; C2) Acinetobacter baumannii; C3) Pseudomonas aeruginosa; C4) Staphylococcus aureus; C5) Salmonella; C6) Klebsiella pneumoniae.

[0015] In a second aspect, the present invention provides the use of inosinic acid in the preparation of a product having an inhibitory effect on bacteria, wherein the bacteria are selected from at least one of C1) to C6): C1) Acinetobacter baumannii ( Acinetobacter baumannii ); C2) Pseudomonas aeruginosa ( Pseudomonas aeruginosa ); C3) Staphylococcus aureus ( Staphylococcus aureus ); C4) Escherichia coli ( Escherichia coli ); C5) Salmonella ( Salmonella enteritidis ); C6) Klebsiella pneumoniae ( Klebsiella pneumoniae ).

[0016] In a third aspect, the present invention provides the use of inosinic acid in the preparation of a product for treating a bacterial infection in a subject.

[0017] In the above application, the bacterial infection may be caused by a single bacterium or a mixed infection caused by multiple bacteria. The bacteria may be caused by at least one of bacteria resistant to antibiotics, bacteria containing resistance genes, and bacteria sensitive to antibiotics. Furthermore, the bacterial infection is caused by at least one bacteria resistant to antibiotics.

[0018] In the above application, the product for treating bacterial infection in a subject may be a drug.

[0019] Furthermore, the dosage form of the drug is selected from any one of tablets, capsules, granules, oral liquids, suspensions, sprays, inhalants, ointments, lotions, gels, eye drops, suppositories, transdermal patches, injections or lyophilized powder injections.

[0020] In the above application, the subject can be a mammal. The mammal can be selected from bovines, equines, felines, canines, lagomorphs, swine, camelids, rodents and primates, including but not limited to cattle, horses, goats, sheep, cats, rabbits, pigs, camels, alpacas, rats, mice, guinea pigs, non-human primates (such as apes, monkeys, baboons, orangutans) and humans, preferably cattle, horses, dogs, goats, sheep, pigs, camels, rats, mice, monkeys and humans.

[0021] In a fourth aspect, the present invention provides a pharmaceutical composition having an inhibitory effect on bacteria, and comprising inosinic acid and a pharmaceutically acceptable carrier.

[0022] In the above-mentioned pharmaceutical composition, the inhibitory effect is specifically manifested as inhibiting the growth of bacteria. The bacteria include at least one of bacteria resistant to antibiotics, bacteria containing resistance genes, and bacteria sensitive to antibiotics. Further, the bacteria include at least one bacteria resistant to antibiotics. The antibiotic is selected from at least one of polymyxin, carbapenems, and tigecycline.

[0023] In a fifth aspect, the present invention provides a method for treating a bacterial infection in a subject, comprising administering a therapeutically effective amount of inosinic acid or a drug comprising inosinic acid as a main active ingredient to the subject.

[0024] In the above method, the bacterial infection may be an infection caused by a single bacterium, or a mixed infection caused by multiple bacteria. The bacteria may be at least one of bacteria resistant to antibiotics, bacteria containing resistance genes, and bacteria sensitive to antibiotics. Furthermore, the bacteria include at least one bacterium resistant to antibiotics. The antibiotic is selected from at least one of polymyxin, carbapenems, and tigecycline.

[0025] In one embodiment of the above treatment method, the dosage form of the drug may include but is not limited to: tablets, capsules, granules, oral solutions, suspensions, sprays, inhalants, ointments, lotions, gels, eye drops, suppositories, transdermal patches, injections or lyophilized powder injections.

[0026] In another embodiment of the above treatment method, the drug can be administered orally, intravenously, intra-arterially, intraperitoneally, intrathecally, transdermally, via the respiratory tract, rectally, topically, or the like.

[0027] In the above method, the subject can be a mammal. The mammal can be selected from bovines, equines, felines, canines, lagomorphs, swine, camelids, rodents and primates, including but not limited to cattle, horses, goats, sheep, cats, rabbits, pigs, camels, alpacas, rats, mice, guinea pigs, non-human primates (such as apes, monkeys, baboons, orangutans) and humans, preferably cattle, horses, dogs, goats, sheep, pigs, camels, rats, mice, monkeys and humans.

[0028] In the above method, the inosinic acid can be administered to the subject at a dosage of 50-150 mg / kg (preferably 100 mg / kg). In a specific embodiment, the administration can be one or more times. The dosage can be converted according to the species of the subject to be administered based on the dosage of experimental animals such as mice, rats, etc. according to the conversion relationship known in the art.

[0029] The invention discloses the application of inosinic acid in preparing a product having an inhibitory effect on bacteria, and experiments have shown that inosinic acid has a good bactericidal effect on a variety of drug-resistant bacteria and is not easy to induce the formation of drug resistance, and can be used as a potential active ingredient for resisting drug-resistant bacterial infection. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 The results of the antimicrobial activity tests of hypoxanthine, xanthine nucleosides, inosine and inosinic acid against drug-resistant bacteria using the broth dilution method; Figure 2 The bactericidal curves of IMP against five drug-resistant bacteria; the upper left is the bactericidal curves of IMP against drug-resistant bacteria E.coli DH5α- mcr-1The lower left shows the sterilization curve of IMP against drug-resistant bacteria. E.coli Bactericidal curve of ZJ807, the upper middle shows the IMP against drug-resistant bacteria E.coli DH5α- bla NDM-1 The sterilization curve of IMP against drug-resistant bacteria is shown in the middle and lower part. E.coli Bactericidal curve of 20SC1DM33, the upper right is IMP against drug-resistant bacteria E.coli DH5α- mcr-1 / bla NDM-1 The lower right shows the sterilization curve of IMP against drug-resistant bacteria. E.coli Sterilization curve of 487; Figure 3 The effects of different concentrations of IMP on drug-resistant bacteria E.coli DH5α- mcr-1 and E.coli DH5α- mcr-1 / bla NDM-1 The results of the observations by scanning electron microscopy (SEM) and transmission electron microscopy (TEM) after treatment; Figure 4 The results of the IMP resistance test are shown in Figure 1. A shows the effect of IMP on resistant bacteria after 30 generations. E.coli DH5α- mcr-1 and E.coli MIC value of ZJ807, B is the MIC value of IMP against resistant bacteria of passage 30 E.coli DH5α- bla NDM-1 and E.coli 20SC1DM33 MIC value, C is the MIC value of IMP against resistant bacteria of passage 30 E.coli DH5α- mcr-1 / bla NDM-1 and E.coli MIC value of 487; Figure 5 Figure 1 is a graph showing the results of IMP treatment of intraperitoneal infection in mice; A is the statistical result of bacterial load in mouse organs after the intraperitoneal infection of mice was treated in the control group (Vehicle), the first IMP treatment group, the second IMP treatment group and the positive control group; B is a photo of the sections of mouse organs after the intraperitoneal infection of mice was treated in the normal control group (Normal Control), the control group (Vehicle), the second IMP treatment group and the positive control group; C is the statistical result of the survival rate of mice within 7 days after the intraperitoneal infection of mice was treated in the normal control group (Normal Control), the control group (Vehicle), the first IMP treatment group, the second IMP treatment group and the positive control group; * p <0.05,**p <0.01,*** p <0.001, **** p <0.0001. DETAILED DESCRIPTION

[0031] In order to make the purpose, technical solution and advantages of the present invention clearer, the technical solution of the present invention will be clearly and completely described below in conjunction with the drawings in the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments, and they should not be understood as limitations on the present invention. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. In the description of the present invention, it should be understood that the terms used are only for descriptive purposes and cannot be understood as indicating or implying relative importance.

[0032] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.

[0033] The strains and their sources used in the following examples are shown in Table 1. ATCC is the American Type Culture Collection, and its website is https: / / www.atcc.org / .

[0034] Table 1 Strains and source information used in the examples of the present invention

[0035] Escherichia coli (Table 1 Escherichia coli )DH5α- mcr-1 With DH5α- bla NDM-1 The construction process is as follows: use a plasmid extraction kit to extract the pACYC184 plasmid from bacteria containing the pACYC184 plasmid; mcr-1 or bla NDM-1 wild E.coli The bacterial solution was used as a template, primers were designed, and PCR was used to add homology arms to the target gene. After amplification, the target fragment was recovered by gel recovery, and then the linearized pACYC184 plasmid was combined with the vector homology arms added. mcr-1 or bla NDM-1 The gene fragment was incubated under the action of homologous recombinase to obtain the recombinant expression vector pACYC184- mcr-1or pACYC184- bla NDM-1 The recombinant expression vector was transformed into DH5α competent cells using the heat shock method, and the cells carrying mcr-1 and bla NDM-1 The recombinant strain DH5α- mcr-1 With DH5α- bla NDM-1 .

[0036] Recombinant expression vector pACYC184- mcr-1 Contains mcr-1 Target fragment, add upstream and downstream homology arms mcr-1 The nucleotide sequence of the target fragment is SEQ ID NO: 1, wherein nucleotides 1 to 26 are upstream homology arms, and nucleotides 27 to 2152 are containing mcr-1 The target fragment, nucleotides 2153-2170 are the downstream homology arm.

[0037] Recombinant expression vector pACYC184- bla NDM-1 Contains bla NDM-1 Target fragment, add upstream and downstream homology arms bla NDM-1 The nucleotide sequence of the target fragment is SEQ ID NO: 2, wherein nucleotides 1 to 19 are upstream homology arms, and nucleotides 20 to 1332 are containing bla NDM-1 The target fragment, nucleotides 1333-1351 are the downstream homology arm.

[0038] Carry at the same time mcr-1 and bla NDM-1 The recombinant strain DH5α- mcr-1 / bla NDM-1 The construction process is as follows: from the above DH5α- mcr-1 Extract the verified pACYC184- mcr-1 Plasmid, using this as a vector, was used to bla NDM-1 Homologous arms are added to both ends of the gene and the homologous recombinase is used to bla NDM-1 Inserted into pACYC184- mcr-1 In the vector, add upstream and downstream homology arms bla NDM-1The nucleotide sequence of the target fragment is SEQ ID NO: 3, wherein nucleotides 1 to 18 are upstream homology arms, and nucleotides 19 to 1331 are containing bla NDM-1 The target fragment, nucleotides 1332-1350 are the downstream homology arm.

[0039] Example 1 Screening of four purine metabolite antibacterial compounds The antibacterial activity of four purine metabolites: hypoxanthine, xanthosine, inosine and inosinic acid (IMP) was detected by broth dilution method. The test strains were DH5α- mcr-1 , DH5α- bla NDM-1 With DH5α- mcr-1 / bla NDM-1 The determination steps take the determination of IMP antibacterial activity as an example: add 100 μL MH broth (MHB) to columns 1-9 of rows 1-5 of a U-bottom 96-well plate. Then, add 100 μL IMP to each well of MHB in row 6 to make the final concentration in the well 14 mg / mL. Then, transfer 100 μL of the drug-containing medium in the plate to row 4 for a 2-fold dilution of the drug, repeat to row 3, and discard 100 μL. Add 100 μL of 1.5×10 6 CFU / mL of bacterial solution, specifically, DH5α- mcr-1 , add DH5α- bla NDM-1 , add DH5α- mcr-1 / bla NDM-1 100 μL MHB was added to the 1st row, 1st column, 9th column as a control (Blank). After culturing in a 37°C incubator for 20 h, the OD of each group was measured using an enzyme-labeled instrument. 600 The remaining three purine metabolites were determined in the same manner as above, with the final concentrations in the plate being Figure 1 Consistent.

[0040] The experimental results are as follows Figure 1 The results showed that among the four purine metabolites, only IMP had antibacterial ability, which was mcr-1 , DH5α- bla NDM-1 With DH5α- mcr-1 / bla NDM-1All showed antibacterial activity. 1.7 mg / mL IMP could significantly inhibit the growth of drug-resistant bacteria, and 3.5 mg / mL concentration could completely inhibit the growth of drug-resistant bacteria.

[0041] Example 2 Determination of the antibacterial activity of IMP against various bacteria The broth dilution method was used to detect the antibacterial ability of IMP against 7 Gram-negative and Gram-positive standard strains and 14 drug-resistant strains of Escherichia coli. The specific steps were as follows: 100 μL of MHB was added to columns 1-12 of rows 1-2 of a U-shaped 96-well plate, and 100 μL of IMP was added to the first column to make the final concentration in the plate 28 mg / mL. Then, 100 μL of the drug-containing culture medium in the plate was transferred to the second column for a 2-fold dilution of the drug, and the dilution was repeated to the tenth column, and then 100 μL was discarded; 100 μL of 1.5×10 6 CFU / mL of the test bacterial solution, 100 μL of blank MHB was added in column 12. After culturing in a 37°C constant temperature incubator for 20 h, the lowest drug concentration corresponding to the well with no visible bacterial growth was the minimum inhibitory concentration (MIC) of the drug against the corresponding strain. The experimental results are shown in Table 2. It can be seen that IMP has an antibacterial effect on a variety of standard bacterial strains and drug-resistant bacteria, with an MIC of 3.5-7 mg / mL. Therefore, IMP is a broad-spectrum antibacterial substance that has antibacterial ability against a variety of bacteria.

[0042] Table 2 Test of the antibacterial effect of IMP on various drug-resistant bacteria

[0043] Note: In Table 2, the unit of IMP is mg / mL, and the concentration unit of meropenem (MEM), colistin (CST), and tigecycline (TGC) is μg / mL. According to the drug susceptibility test standards for Enterobacteriaceae established by the American Clinical and Laboratory Standards Association, the above-mentioned bacteria containing drug resistance genes E.coli All meet the requirements for corresponding antibiotic-resistant bacteria.

[0044] Example 3 Bactericidal curve of IMP against drug-resistant bacteria This example uses a time-kill curve to evaluate the bactericidal effect of IMP on drug-resistant bacteria. Specifically, the overnight cultured mcr-1 The gene of Escherichia coli ( E.coli DH5α- mcr-1 and E.coli ZJ807), including bla NDM-1 The gene of Escherichia coli ( E.coli DH5α- bla NDM-1 andE.coli 20SC1DM33) and carry mcr-1 and bla NDM-1 Escherichia coli ( E.coli DH5α- mcr-1 / bla NDM-1 and E.coli 487) were transferred to antibiotic-free LB broth at a dilution of 1:100 and cultured until mid-logarithmic phase, after which the bacterial concentration was adjusted to 1×10 8 CFU / mL. IMPs were added to the adjusted bacterial suspension at final concentrations of 1.7, 3.5, 5, and 7 mg / mL, and the group with non-antibiotic LB broth was set as the untreated control group, and the suspension was shaken in a shaker. 100 μL of bacterial solution was taken at 0, 3, 6, 9, and 24 h, respectively, and suspended in 900 μL PBS. After ten-fold dilution, 100 μL of the diluted suspension was spread on the LB agar plate, and the bacterial colonies were counted after inverted culture at 37 ° C for 20 h.

[0045] The experimental results are as follows Figure 2 As shown in the figure, it can be seen that for the above six drug-resistant strains, 3.5 mg / mL IMP can inhibit the proliferation of bacteria; 5 mg / mL IMP can completely kill them within 9 hours. E.coli ZJ807, and reduced the survival of the other five resistant bacteria by 10% compared with the control group. 4 times; 7 mg / mL IMP can completely eliminate drug-resistant bacteria within 6 hours. Therefore, IMP has a strong bactericidal ability, and high concentrations of IMP can quickly kill multiple drug-resistant bacteria in a short time.

[0046] Example 4 Scanning and transmission electron microscopy observation of drug-resistant bacteria after IMP treatment Overnight culture E.coli DH5α- mcr-1 and E.coli DH5α- mcr-1 / bla NDM-1 The bacterial solution was transferred to the antibiotic-free LB broth at a ratio of 1:100 and cultured with shaking until the logarithmic growth phase. Then, the bacterial turbidity was adjusted to OD using PBS. 600 The concentration of IMP was about 0.5, and IMP with a final concentration of 1.5 and 3 mg / mL was added to the bacterial solution, and the group with only PBS was set as the untreated control group. After incubation, the bacteria were washed with PBS and fixed with electron microscopy fixative at 4°C in the dark for 30 min, and then observed using scanning electron microscopy (SEM) and transmission electron microscopy (TEM).

[0047] The experimental results are as follows Figure 3 As shown, it can be seen that IMP can causeE.coli DH5α- mcr-1 and E.coli DH5α- mcr- 1 / bla NDM-1 Damage to the membrane wall leads to abnormal morphology and leakage of contents.

[0048] Example 5 IMP resistance passage test Will contain mcr-1 Gene-resistant bacteria E.coli DH5α- mcr-1 and E.coli ZJ807, including bla NDM-1 Gene-resistant bacteria E.coli DH5α- bla NDM-1 and E.coli 20SC1DM33 and carry mcr-1 and bla NDM-1 Gene-resistant bacteria E.coli DH5α- mcr-1 / bla NDM-1 and E.coli 487 was cultured to mid-logarithmic phase and transferred to MHB broth containing IMP at 0.25×MIC, 0.5×MIC, 1×MIC, 2×MIC and 4×MIC concentrations at a ratio of 1:100 for 24 h, which was recorded as generation 1. After 24 h, the culture medium with the highest IMP concentration where bacterial growth was visible was selected and transferred to MHB containing IMP at 0.25×MIC, 0.5×MIC, 1×MIC, 2×MIC and 4×MIC concentrations at a ratio of 1:100 for 24 h, which was recorded as generation 2. The above steps were repeated until generation 30, and the culture medium used for subculture in each generation was streaked on an anti-MH agar plate, and the growing single colony was selected and transferred to MH broth medium. After the culture became turbid, the MIC value of IMP against it was determined.

[0049] The experimental results are as follows Figure 4 As shown, it can be seen that IMP is not easy to induce the formation of bacterial resistance.

[0050] Example 6 IMP treatment of intraperitoneal infection in mice BALB / c female mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., 6-8 weeks old) were weighed and divided into groups, with 6 mice in each group. 200 μL of 2.0×10 8 CFU / mL E.coli ZJ807 or E.coliWhen the mice showed symptoms of bacterial infection such as wilting, chills, depression and diarrhea, each group of mice was given different treatments. Specifically, the control group (Vehicle) was intraperitoneally injected with 200 μL PBS, the IMP first treatment group was injected with 50 mg / kg IMP, the IMP second treatment group was injected with 100 mg / kg IMP, and the positive control group was injected with 1 mg / kg polymyxin (CST, for infection E.coli ZJ807 mice) or 1 mg / kg of polymyxin combined with meropenem (CST+MEM, for infection E.coli 487 mice), and the survival rate of the mice was observed and recorded for 7 days after one injection. The bacterial load in the liver, spleen, lung and kidney of the mice was counted, and the pathological damage of the organs was observed.

[0051] The experimental results are as follows Figure 5 As shown, it can be seen that for E.coli ZJ807 and E.coli In the case of intraperitoneal infection of mice caused by Bacillus 487, 100 mg / kg of IMP can significantly reduce the bacterial load in the mouse organs, alleviate organ damage and lesions, and ultimately improve the survival rate of mice. mcr-1 Gene-resistant Escherichia coli and carriers mcr-1 and bla NDM-1 It has a good therapeutic effect on abdominal infections caused by gene-resistant Escherichia coli.

[0052] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. The use of inosinic acid in the preparation of a product having an inhibitory effect on drug-resistant bacteria, characterized in that: The drug-resistant bacteria are resistant to antibiotics, and the antibiotics are selected from at least one of A1) to A3): A1) Polymyxin; A2) Carbapenems; A3) Tigecycline.

2. The use according to claim 1, characterized in that: The drug-resistant bacteria contain a drug-resistant gene, and the drug-resistant gene is selected from at least one of B1) to B3): B1) Polymyxin resistance genes; B2) Carbapenem resistance genes; B3) Tigecycline resistance gene.

3. The use according to claim 2, characterized in that: The polymyxin resistance gene is mcr ; The carbapenem resistance gene is bla , the tigecycline resistance gene is tet(X) .

4. The use according to any one of claims 1 to 3, characterized in that: The product is a medicine, in which the inosinic acid is the main active ingredient.

5. The use according to claim 4, characterized in that: The dosage form of the drug is selected from any one of tablets, capsules, granules, oral liquids, suspensions, sprays, inhalants, ointments, lotions, gels, eye drops, suppositories, transdermal patches, injections or freeze-dried powder injections.

6. The use according to any one of claims 1 to 5, characterized in that: The drug-resistant bacteria are selected from at least one of C1) to C6): C1) Escherichia coli; C2) Acinetobacter baumannii; C3) Pseudomonas aeruginosa; C4) Staphylococcus aureus; C5) Salmonella; C6) Klebsiella pneumoniae.

7. Use of inosinic acid in the preparation of a product having an inhibitory effect on bacteria, characterized in that: The bacteria are selected from at least one of C1) to C6): C1) Acinetobacter baumannii; C2) Pseudomonas aeruginosa; C3) Staphylococcus aureus; C4) Escherichia coli; C5) Salmonella; C6) Klebsiella pneumoniae.

8. Use of inosinic acid in the preparation of a product for treating a bacterial infection in a subject.

9. The use according to claim 8, characterized in that: The bacterial infection is caused by at least one of bacteria resistant to antibiotics, bacteria containing drug-resistant genes, and bacteria sensitive to antibiotics.

10. A pharmaceutical composition, characterized in that The pharmaceutical composition has an inhibitory effect on bacteria and comprises inosinic acid and a pharmaceutically acceptable carrier.

Citation Information

Patent Citations

  • Micromolecule metabolite for facilitating antibiotic to eliminate pathogenic bacteria

    CN104606219A

  • Application of hypoxanthine nucleotide in preparation of anti-infective drugs

    CN112569251A

  • Application of adenosine or adenosine monophosphate in preparation of Anti-infective drugs

    WO2023115757A1

Cited By

  • Pharmaceutical composition and application thereof

    CN120284976A

  • A pharmaceutical composition and uses thereof

    CN120284976B